Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries
Related news for (MRZM)
- Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
- Marizyme CEO Delivers Business Update
- InvestmentPitch Media Video Features Marizyme’s CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device
- The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News